GP40141 (romiplostim biosimilar) / Geropharm - LARVOL DELTA

Multicenter Single-Blind Randomized Controlled Trial of the Romiplostim Biosimilar. (PubMed, EJHaem) - P3 | "The results support the biosimilar romiplostim as an equivalent and comparable treatment option to the reference drug for patients with persistent or chronic ITP. NCT06497036."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Optimization of Romiplostim Biosimilar Efficacy Trial Using In Silico Clinical Trial Approach for Patients With Immune Thrombocytopenia. (PubMed, Clin Pharmacol Drug Dev) - "Since the planned trial includes both patients naïve to therapy with thrombopoietin receptor agonists and nonnaïve patients, various expected ratios of naïve to nonnaïve patients (1:1, 1:2, 1:3) and the percentage of nonnaïve patients who previously received eltrombopag (0% or 30%) were assessed across 200 ISCTs performed for each scenario. Differences in power between the 10- and 26-week end points did not exceed 4%. The analysis of ISCT results allowed for an effective reduction of uncertainty in the biosimilar development of GP40141, demonstrating the appropriateness of using the 10-week efficacy end point as the primary one."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia (clinicaltrials.gov) - P3 | N=160 | Active, not recruiting | Sponsor: Geropharm

New P3 trial • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity. (PubMed, Clin Pharmacol Drug Dev) - P1 | "Additionally, values of intersubject variability, previously unreported for romiplostim in a healthy subject population, were derived. Covariate analysis, conducted during model development, as well as visual diagnostics and model-based simulations, demonstrated the absence of significant differences in PK and PD between GP40141 and romiplostim-ref."

Journal • PK/PD data • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

A randomized, double-blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers. (PubMed, Pharmacol Res Perspect) - P1 | "This study demonstrates the PD similarity of GP40141 to the reference romiplostim. Both treatments had comparable safety profiles (NCT05652595)."

Clinical • Journal • PK/PD data

Comparability of biosimilar romiplostim with originator: Protein characterization, animal pharmacodynamics and pharmacokinetics. (PubMed, Biologicals) - "The serum concentrations of romiplostim were determined using a modified colorimetric enzyme-linked immunosorbent assay (ELISA). The data obtained allow us to assert the similarity of the biological action of Nplate® and GP40141."

Journal • PK/PD data • JAK2

Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141 (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Geropharm

New P1 trial